| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/12/2023 | 75.44% | Keybanc | → $4 | Initiates Coverage On | → Overweight |
What is the target price for Standard BioTools (LAB)?
The latest price target for Standard BioTools (NASDAQ: LAB) was reported by Keybanc on July 12, 2023. The analyst firm set a price target for $4.00 expecting LAB to rise to within 12 months (a possible 75.44% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Standard BioTools (LAB)?
The latest analyst rating for Standard BioTools (NASDAQ: LAB) was provided by Keybanc, and Standard BioTools initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Standard BioTools (LAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Standard BioTools, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Standard BioTools was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
Is the Analyst Rating Standard BioTools (LAB) correct?
While ratings are subjective and will change, the latest Standard BioTools (LAB) rating was a initiated with a price target of $0.00 to $4.00. The current price Standard BioTools (LAB) is trading at is $2.28, which is within the analyst's predicted range.